Neurol. praxi. 2021;22(3):226-230 | DOI: 10.36290/neu.2021.027

Long-term management of oral cladribine treatment in multiple sclerosis

MUDr. Radek Ampapa¹, MUDr. Michal Dufek, Ph.D.², MUDr. Pavel Hradílek, Ph.D.³, MUDr. Ivana Kovářová⁴, prof. MUDr. Jan Mareš, Ph.D.⁵, MUDr. Alena Martinková⁶, MUDr. Marek Peterka⁷, doc. MUDr. Pavel Štourač, Ph.D.⁸, MUDr. Aleš Tvaroh, Ph.D.^{9, 10}, MUDr. Marta Vachová^{4, 9}, prof. MUDr. Martin Vališ, Ph.D.¹¹

¹ Neurologické oddělení, Nemocnice Jihlava

² 1. neurologická klinika LF MU a FN u sv. Anny, Brno

³ Neurologická klinika FN, Ostrava

⁴ Neurologická klinika 1. LF UK a VFN, Praha

⁵ Neurologická klinika LF UP a FN, Olomouc

⁶ Neurologická klinika, Nemocnice Pardubického kraje, a. s., Pardubice

⁷ Neurologická klinika LF UK a FN, Plzeň

⁸ Neurologická klinika LF MU a FN, Brno Bohunice

⁹ Neurologické oddělení, Krajská zdravotní, a. s., Nemocnice Teplice, o. z.

¹⁰ Merck, spol. s r. o.

¹¹ Neurologická klinika LF UK a FN, Hradec Králové

Autoři jsou uvedeni v abecedním pořadí

Oral cladribine is a high efficacy disease-modifying drug for treatment of multiple sclerosis. Its mode of action represents a selective immune-reconstitution resulting in simply dosing in two annual curses followed by a sustained period of a potential remission. Our work is aimed to an initiation of oral cladribine treatment, monitoring schedule and types of terapeutic response. Consequent treatment options are suggested based on eventual disease activity after cladribine courses. Furthermore, cladribine is discussed from perspective of pregnancy planning and vaccination.

Keywords: multiple sclerosis, cladribine, therapeutic response.

Received: April 26, 2021; Revised: April 27, 2021; Accepted: April 27, 2021; Prepublished online: April 27, 2021; Published: October 1, 2021  Show citation